4dmedical Ltd. · ASX:4DX
4dmedical — Shareholder Meeting (November 2022)
23 slides from 4dmedical's shareholder meeting presentation, Nov 3, 2022
Slide 1: The Future of Lung Health – Annual General Meeting
The Future of Lung Health Annual General Meeting 3 November 2022 10:00 am 4DMedical Limited (ASX:4DX)
Slide 2: Disclaimer
Disclaimer Thi s presentation has been prepared by 4DMedical Limited (ACN 161 684 831) (Compa ny or 4DMedical). This presentation contains summary i nformation about the Company, i ts s ubsidiaries a nd the entities, businesses and assets they own a nd operate (Group) and their activi ties current a
Slide 3: 2022 AGM agenda
2022 AGM agenda 1. Opening & introductions 2. Procedural matters 3. Chairman’s address 4. CEO’s presentation 5. Formal business 6. Closing remarks 4DMedical Limited (ASX:4DX) AGM Presentation| November 2022 3
Slide 4: Board of directors
Board of directors Advisory board Dr SAM HUPERT MBBS Advisory Board Member BRUCE RATHIE Dr ANDREAS FOURAS PhD LIL BIANCHI Dr ROBERT A. FIGLIN MD Co-founder and Chief Executive Officer of Pro Non-Executive Chairman Managing Director and Chief Non-Executive Director; Chair, Non-Executive Director Medi
Slide 5: Chairman’s Address
Chairman’s Address BRUCE RATHIE Non-Executive Chairman Experienced lawyer, investment banker and company director.
Slide 6: FY22 financial summary
FY22 financial summary • 4DMedical reported a net cash balance of $51.11 $51.11m $1.05m million at 30 June 2022, with zero debt. Cash reserves Sales and maintenance revenue • Total income is $13.37 million, up 132%, comprising $1.05 million in operating revenue and $12.32 million $13.37m $37.03m in
Slide 7: Chief Executive Officer
Chief Executive Officer Dr ANDREAS FOURAS PhD Managing Director Award-winning aerospace engineer and innovator responsible for the conception and development of 4DMedical’s core technologies.
Slide 8: Accelerating commercial progress
Accelerating commercial progress Mar- Jul 22 31 Aug 22 30 Sep 22 19 Oct 22 25 Oct 22 Making Major success Continuing 4DMedical 4DMedical significant as Vanderbilt engagement progress release of progress across ‘burn pit’ trial with legislators, towards full CT LVAS™ in all areas of hits primary advo
Slide 9: Global market opportunity: USD $31.3 billion p.a. global spend
Global market opportunity: USD $31.3 billion p.a. global spend • The market segmentation by the number of procedures. Market Opportunity by Country2 Country Spend (USD) Procedures US 13,716M 73.5M X-ray Procedures 253m Others 4,964M 59.8M Germany 2,678M 20.3M Technology Expenditure USD $14.5 bi l li
Slide 10: U.S. market opportunity: Veterans’ health in the United States
U.S. market opportunity: Veterans’ health in the United States The U.S. PACT Act is set to appropriate USD $280 billion in additional funding over ten years for affected veterans • 3.5 million U.S. troops have been exposed to toxic burn pits since 1991. • Recognition of the impact of Post-Deployment
Slide 11: Demonstrating clinical utility: Reliability & repeatability
Demonstrating clinical utility: Reliability & repeatability Age 30’s Indications Baseline Sex Male Healthy male with no signs of disease Summary • XV LVAS® validated assessment of regional lung function. • XV Technology® proved the reliable repeatability of findings. TV VH VDP 0.68 42.8 13.0 • XV Te
Slide 12: Demonstrating clinical utility: Silicosis
Demonstrating clinical utility: Silicosis Age 36 Indications Baseline Sex Male Novel treatment for a Severe Progressive Silicosis related Occupational Lung Disease Summary • At baseline, there are advanced changes of chronic, complicated silicosis as marked by nodular coalescence and fibrosis in the
Slide 13: Demonstrating clinical utility: COPD
Demonstrating clinical utility: COPD Age 60 Indications Baseline Sex Male Prior biologics therapeutic for re-current exacerbation of moderate obstructive lung disease Summary • SOB for further investigation. • At baseline CT was unremarkable. Placed on biologics for history of exacerbation. TV VH VD
Slide 14: Demonstrating clinical utility: Long Covid-19
Demonstrating clinical utility: Long Covid-19 Age 52 Indications Baseline Chest CT: Acute COVID- 19 infection Sex Female Long Covid symptoms Summary • Patient hospitalised for COVID-19. • During admission chest CT observed peripheral ground-glass and consolidative pulmonary opacities. (no XV LVAS® i
Slide 15: Demonstrating clinical utility: Assessment of hiatal hernia
Demonstrating clinical utility: Assessment of hiatal hernia Age 69 Indications Hiatal Hernia CT scan XV LVAS® scan Sex Female • History of COVID-19 • Gastric esophageal reflux disease • Recurrent chest infections Summary • CT imaging indicated a large hiatal hernia. • XV LVAS® demonstrated a greater
Slide 16: Commercialisation: Two pillar strategy
Commercialisation: Two pillar strategy Clinical trials Commercial pilots Research partners delivering the body of Physicians gaining familiarity with technology and scientific evidence for clinical use business case for clinical adoption Who Why Who Why • Eminent researchers and • Diagnostics, treat
Slide 17: Commercialisation: Johns Hopkins trial results
Commercialisation: Johns Hopkins trial results • Has the capability of assessing regional ventilation defects, which is critical to optimising therapies. • Is a repeatable lung assessment tool in a cohort of COPD patients. • Illustrates distribution of airflow within the lungs, corresponding with CO
Slide 18: Commercialisation: Burn pit trial results
Commercialisation: Burn pit trial results • PDRS is not detectable by Spirometry, X-ray or XV clinical trial outputs displaying ventilation variation CT only via surgical biopsy. HEALTHY DISEASED • 4DMedical’s XV Technology® detects the presence of constrictive bronchiolitis (‘CB’). • Quantitative s
Slide 19: Progressing clinical trials
Progressing clinical trials Completed Studies Imaging Complete Imaging in Progress Pneumonitis Lung Transplant BLVR PH COPD Paediatric CF Cedars Sinai Duke University University of Miami Cleveland Clinic Oregon Health & Johns Hopkins Science University XV LVAS® XV LVAS® XV LVAS® VQ™ XV LVAS® XV LVAS
Slide 20: CT LVAS™ product release in Australia
CT LVAS™ product release in Australia • CT LVAS™ provides an similar report to XV LVAS® but utilises widely available CT imaging infrastructure (instead of X-ray). • Provides clinicians and patients with the benefits of XV Technology®, significantly growing the accessibility of functional lung imagi
Slide 21: An evolving product pipeline
An evolving product pipeline 4DMedical Current product XV LVAS® CT LVAS™ CT:VQ software offering release (ventilation) (ventilation) (ventilation / perfusion) Image acquisition modality X-ray XV Scanner CT (exi sting hospital & ra diology (exi sting hospital & ra diology (4DMedical hardware) ha rdwa
Slide 22: An evolving product pipeline: Software offering
An evolving product pipeline • The simplicity of offering (Ventilation or Perfusion) with the flexibility of distribution Image acquisition modality Fluoroscopy Computed Tomography XV Scanner (X-ray) (CT) (XV) Ventilation (XV) XV LVAS® CT LVAS™ Rapid XV LVAS® Software offering Rapid X-ray Perfusion
Slide 23: The Future of Lung Health
The Future of Lung Health 4DMedical Limited (4DX) Corporate Administration Media Enquiries CFO Company Secretary TCN Simon Glover Melanie Leydin Julia Maguire sglover@4dmedical.com companysecretary@4dmedical.com julia@thecapitalnetwork.com.au